Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001

Allyx Therapeutics announced that it has been awarded a $3.3 million grant from the National Institutes of Health. This funding will support further investigation of Allyx’s lead clinical asset, ALX-001, a highly-selective oral therapy in development for the treatment of Alzheimer’s disease and Parkinson’s disease.